UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 11, 2005
DOVPHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | | 000-49730 | | 22-3374365 |
| (State or Other Jurisdiction of Incorporation) | | (Commission File No.) | | (IRS Employer Identification No.) |
| | | | | |
| | 433 Hackensack Avenue, Hackensack, NJ 07601 | |
| | (Address of Principal Executive Offices) (Zip Code) | |
| | | | | |
| | Registrant's Telephone Number, including Area Code:(201) 968-0980 |
| | | | | |
| | Not applicable | |
| | (Former Name or Former Address, if Changed Since Last Report) | |
| | | |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)) |
| | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) |
ITEM2.02. RESULTS OF OPERATION AND FINANCIAL CONDITION.
On March 11, 2005, registrant announced its financial results for the quarter and fiscal year ended December 31, 2004. The text of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this current report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this current report, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section unless registrant incorporates it by reference into a filing under the Securities Act of 1933, as amended.
ITEM 5.02a(b). DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
Dr. Bernard Beer resigned from the board effective the end of March 15, 2005. Dr. Beer had resigned as president effective a year earlier.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits. The following exhibits are filed with this current report on Form 8-K.
Exhibit No. | Title |
| | |
| 99.1 | Press Release, dated March 11, 2005, of DOV Pharmaceutical, Inc. |
| | |
| 99.2 | Letter dated March 15, 2005, from Dr. Bernard Beer giving notice of his resignation as director. |
| | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | DOV Pharmaceutical, Inc. |
|
|
|
| Date: March 15, 2005 | By: | /s/ Arnold Lippa |
| |
Arnold Lippa |
| | Chief Executive Officer |
EXHIBIT INDEX
Exhibit No. | Title |
| | |
| 99.1 | Press Release, dated March 11, 2005, of DOV Pharmaceutical, Inc. |
| | |
| 99.2 | Letter dated March 15, 2005, from Dr. Bernard Beer giving notice of his resignation as director. |
| | |
